Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects

Sponsor
Sun Yat-sen University
Study ID
NCT02147925
Phase
PHASE4
Status
Completed

Conditions

  • Non-alcoholic Fatty Liver Disease

Eligibility Criteria

Sex
ALL
Age
30 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide combined with metformin — DRUG
    Liraglutide, 0.6mg per day for the first week, and will be increased to 1.2mg per day for the second week, and finally 1.8mg per day since the third week
  • Insulin glargine combined with metformin — DRUG
    The initial dose will be 0.2 unit/kg/d
  • Sitagliptin combined with metformin — DRUG
    The dose throughout the study will be 100mg per day.

Study Details

The aim of this study is to explore the effectiveness of liraglutide combined with metformin in non-alcoholic fatty-liver disease patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and insulin glargine in combination with metformin.

Key Dates

Start date
Aug 31, 2014
Status verified
Oct 2017
Primary completion
Apr 30, 2017
Completion
Apr 30, 2017

Study Design

Enrollment
75 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Liraglutide
    Liraglutide combined with metformin
  • Active Comparator: Insulin glargine
    Insulin glargine combined with metformin
  • Active Comparator: Sitagliptin
    Sitagliptin combined with metformin

Primary Outcome Measure

Intrahepatic lipids (IHL) [ Time Frame: 26-week ]

Related Studies